PERI-TREATMENT ANTIBIOTIC EXPOSURE AND SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS: A LARGE REAL-WORLD PROPENSITY-MATCHED COHORT STUDY (AASLD 2026) - Oct 6, 2026 - Abstract #4202; Pres time: Nov 8, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; "Adults with HCC (ICD-10 C22.0) who received any ICI (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, tremelimumab, tislelizumab, or toripalimab) on or after HCC diagnosis were included, with first ICI as the index event...Groups were matched 1:1 on demographics, cirrhosis, comorbidities (diabetes, COPD, alcohol-related disorders), prior systemic therapy (sorafenib, lenvatinib, regorafenib, cabozantinib), microbiome-modulating comedications (rifaximin, proton pump inhibitors), and alpha-fetoprotein ≥400 ng/mL... In the largest realworld HCC ICI cohort to date (6,628 matched), antibiotic exposure at ICI initiation was associated with a 42% increased hazard of death, whereas exposure 3 to 12 months earlier was not. This window-specific harm argues against confounding by patient frailty and supports a microbiome-mediated interaction with ICI efficacy, favoring antibiotic stewardship at ICI initiation in HCC."
Checkpoint inhibition • Clinical • Real-world • Real-world evidence • Chronic Obstructive Pulmonary Disease • Diabetes • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Oncology • Respiratory Diseases • Solid Tumor • AFP
|
|
Mazen Elsheikh1; Hamza Salim2; Osamah Salim3; Sherry Fares1; Karim Adhem1; Mohamad Ali Ibrahim1; Chandni Bhagtaney1; Angela Aguilar1; Ximena Ramirez Morales1; Prasun Jalal1
|